Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer

Launched by RENJI HOSPITAL · Jun 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new type of imaging test to help doctors better diagnose a common type of lung cancer called non-small cell lung cancer. The test uses a special scan called PET/CT that looks for specific markers (called Trop2 and EpCAM) on lung nodules, which are small lumps in the lung. Researchers want to see if this new scan can give clearer information compared to the standard PET/CT scan currently used, helping doctors tell whether a lung nodule is cancerous or not without needing more invasive procedures.

People aged 18 to 80 who have lung nodules at least 8 millimeters in size, and whose scans suggest possible non-small cell lung cancer, might be eligible to join. Participants will undergo the new PET/CT scan as well as the usual imaging tests and may have surgery or a biopsy to confirm the diagnosis. The study is currently recruiting and requires that patients or their family members agree to participate by signing a consent form. Pregnant women, those with certain health issues, or those who have recently had similar radiation tests may not be able to join. Overall, this study hopes to improve how lung cancer is diagnosed, making it easier and less invasive for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18-80 years;
• • 2. Imaging studies suspecting non-small cell lung cancer;
• • 3. Solid lung nodules (≥8 mm in diameter) diagnosed by chest ct, which are subject to 18F-FDG PET/CT and surgical resection/biopsy of lung nodules according to the NCCN guideline specifications for NSCLC in the 2024 edition;
• • 4. Patients or family members agreed to participate in this clinical study and signed an informed consent form.
• Exclusion Criteria:
• • 1. Women during pregnancy and lactation;
• • 2. Persons with a history of surgery and trauma that significantly affects metabolic distribution and anatomical structure;
• • 3. Persons with severe other systemic diseases or known hypersensitivity to humanized monoclonal antibody products;
• • 4. Patient is unable to cooperate in completing the PET/CT examination;
• • 5. Patient has participated in other clinical studies within the past year that have resulted in radiation exposures in excess of an effective dose of 50 mSv, in addition to the radiation exposures anticipated from participation in this clinical study;
• • 6. Patient should not participate in this clinical trial in the opinion of the investigator.